Soleno Therapeutics IncFRA Soleno Stock Report

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 20 full-time employees. The company went IPO on 2014-10-23. The firm is focused on the development and commercialization of therapeutics for the treatment of rare diseases. Its lead drug, Diazoxide Choline Controlled-Release tablets (DCCR), is a potent ATP-sensitive potassium (KATP) channel activator. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like Prader-Willi syndrome (PWS) to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance, and reduce body fat. The company appears that many of the problematic behaviors in conditions like PWS may have hyperphagic drive as a root cause and may therefore be improved by addressing hyperphagia. The firm has a Fast-Track designation for DCCR in PWS and an orphan drug designation for the drug in the United States and European Union. Its development pipeline includes proposed diagnostic devices for asthma in children.